Eye on Emerging Data on Small Molecule Inhibitors in IBD

CME : 0.5 + more
Start Date :  Jan 07, 2021End Date :  Jan 07, 2022

Organized by :   Medscape, LLC

Specialties :   Gastroenterology

Fees Fee :   Starting From Free

Conference Summary

Eye on Emerging Data on Small Molecule Inhibitors in IBD is organized by Medscape, LLC.

CME / ABIM MOC / CE Released: 1/7/2021
Valid for credit through: 1/7/2022

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Goal Statement:
Current treatments for more severe inflammatory bowel disease (IBD) are ineffective in a large proportion of patients. The goal of this initiative is to raise awareness of and educate on the new and emerging targeted small molecules for the treatment of patients with IBD.

Upon completion of this activity, participants will:
• Recent clinical data on emerging agents for moderate to severe IBD
• The mechanism of action (MOA) of emerging treatments for moderate to severe IBD

Credit Info

  • CME : 0.5
  • MOC : 0.5
Contact Us

Toll free Number

1(800) 826-2059



Chat Assistant

Live Chat